Live
Endpoints NewsInside Makary’s ouster; Another win for Lilly’s triple-G; and more10x Genomics BlogSerge Saxonov (TXG) reports multiple 2026 sales and a 35,270-share RSU grant - Stock Titan10x Genomics BlogTXG (NASDAQ) Form 144: RSU grant 26,276 shares; insider sold 7,826 - Stock Titan10x Genomics NewsAdam Taich files to sell 32,648 shares | TXG SEC Filing - Form 144 - Stock TitanMerck & Co.Spotlight On: Five things to watch at ASCO - FirstWord PharmaNovo NordiskBiopharma bites: CHMP backs oral Wegovy, Retro's financing, plus CVC's bid for Recordati - FirstWord PharmaEndpoints NewsFDA clears Gilead's hepatitis D drug, four years after prior rejectionClinical OMICsFungal Adjuvant Mannadjuvant Extends mRNA COVID-19 Vaccine ProtectionsEndpoints NewsGOP lawmaker asks Trump administration to curb China biotech dealsClinical OMICsHow Colorectal Tumors Escape KRAS Inhibitors IdentifiedClinical OMICsFDA Approves Datroway as First-Line Therapy for Triple-Negative Breast CancerFDA News ReleasesFDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
FierceBiotech Feb 4, 2026

Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates

Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates

Original
Body unavailable. Use the original source.